Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion

To join this study, you need to be an adult (18 years or older) and have advanced non-small cell lung cancer (NSCLC) with a specific gene change called an EGFR exon 20 insertion. You must also be currently receiving amivantamab as your only cancer treatment within France under a special access program.

Your doctor must have confirmed that your cancer has started to progress while on amivantamab. You also need to be covered by the French National Health Insurance or a similar private insurance.

Unfortunately, you can't join if you're taking amivantamab alongside another cancer treatment, or if you're not able to provide the necessary blood samples when your cancer progresses.

If you decide to take part, the first step is to have a chat with the study team and read through all the information. If you're happy to proceed, you'll be asked to sign a consent form, which means you understand and agree to the study procedures.

The main part of your involvement happens if and when your doctor confirms that your cancer is growing again while you're on amivantamab. At this point, the study team will take a small amount of blood from you. This is a routine blood draw, usually two small tubes (about 20ml in total).

If it's possible and your doctor agrees, a small sample of your tumour tissue might also be collected at the same time. These samples will then be sent to a specialist lab for detailed analysis to look for changes in your cancer cells. There are no extra hospital visits needed for this study; the samples are collected during your usual medical appointments. The study continues for as long as needed to collect these samples after your disease has progressed on amivantamab.